Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Private Equity Firm Acquires Pfanstiehl

by Rick Mullin
April 8, 2013 | A version of this story appeared in Volume 91, Issue 14

Continuing a trend of private equity investment in U.S. pharmaceutical chemical companies, Med Opportunity Partners has acquired Ferro Pfanstiehl Laboratories, a manufacturer of active pharmaceutical ingredients and excipients. Greenwich, Conn.-based MedOp will pay Ferro $17 million up front and up to $8 million more in incentive payments over two years. Pfanstiehl is positioned to benefit from a market shift toward excipients manufactured to current Good Manufacturing Practice standards, according to James A. Breckenridge, a founding member of Med­Op and new chairman of Pfanstiehl. The deal is the latest in a scheme by Ferro to divest itself of noncore businesses.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.